In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
about
Combination Approaches with Immune-Checkpoint Blockade in Cancer TherapyCurrent clinical trials testing the combination of immunotherapy with radiotherapy.Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols.Following the Preclinical Data: Leveraging the Abscopal Effect More Efficaciously.Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials.Trial Watch: Immunotherapy plus radiation therapy for oncological indications.The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysisProspects for the use of ipilimumab in treating advanced prostate cancer.Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.Emerging Opportunities and Challenges in Cancer Immunotherapy.Embracing rejection: Immunologic trends in brain metastasis.Radiotherapy and immunotherapy: a beneficial liaison?Modulating Both Tumor Cell Death and Innate Immunity Is Essential for Improving Radiation Therapy Effectiveness.Radiation therapy and the abscopal effect: a concept comes of age.Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.Abscopal Effects: Case Report and Emerging Opportunities.Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone.Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.Radiation effects on antitumor immune responses: current perspectives and challenges.Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences.Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases.Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model.Tumor Immuno-Environment in Cancer Progression and Therapy.Defining the role of the tumor vasculature in antitumor immunity and immunotherapy.Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges.Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials.Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.Cancer Vaccines in Ovarian Cancer: How Can We Improve?Beyond checkpoint inhibition - Immunotherapeutical strategies in combination with radiation.Abscopal effect of radiotherapy combined with immune checkpoint inhibitorsEffective nivolumab sequential thoracic radiotherapy in elderly patients with advanced squamous cell lung cancer: did radiation therapy play a role? A case report
P2860
Q28066199-957F33D0-0D22-43FD-A11A-91316D3D4550Q30356447-0BDC6AE2-83AB-4093-B9CB-CC8475364835Q30360210-57DA50EF-9F13-4A84-9493-924D735CA64FQ36356635-F408F97D-8F27-4127-9AE4-5D14BE92EA4AQ37059799-BA98D07B-9FD3-4484-9B7B-1F6704E6E2D4Q37308207-6A0BFFEE-2C93-42D3-84E5-93C9C225599FQ37729387-87BFD1E2-328A-454D-BF80-A4CBACE856BBQ38677420-26105864-83B9-4561-BC2D-C3144996B380Q38760078-BB40279E-EB16-47F6-8060-F49B1D64838BQ38809772-2EBBE8D5-1BA0-4847-9408-FBB2AC175E61Q38953017-75614A46-317D-4283-AA7A-08DBE57F78C7Q39017268-ED572E35-83D4-4C52-83CD-121939369326Q39365749-C6415F43-AB94-498D-81E2-9939DC82D5BAQ40071223-31697112-E122-4EBA-B1B6-41A94B03B6CAQ41520240-2DF0973E-EB3E-4EBC-9B45-2DC4D5F55179Q42222358-1C482312-0A64-4025-8055-8B25F72B81B5Q47178368-1C631DB4-883B-4924-88EE-D18B6B482E8EQ47405972-5374F832-5D86-4A09-AE78-6CFB246D85B6Q47703452-A5757D47-7C61-43EE-AF92-490F2A27E284Q47899811-C3C96329-B958-4CD2-B324-595428959BFEQ48193685-1E300DF3-6B03-4D8C-B485-806BAC23F707Q48238878-B187CC43-C9A0-4778-9B78-8C786D34AACCQ49592937-6C2FCCFC-8C1D-41B4-8E9A-CE1FBE0CCF10Q49679692-8D310B96-EF80-401C-B66A-2EA8244667BBQ50044559-BEA2D7BE-6B1C-42D3-8CF3-09028F7A239BQ50125923-21133A0E-BBAA-43CA-A492-B81BDF765C4FQ52597555-4F16C29C-E4A4-49EA-85F8-9C6B2880747FQ52602002-01FEABF9-6D19-4A55-812C-FD897E40C7F7Q54385315-61789A56-DF18-473F-931F-A231601FDEA3Q55316979-AB98F49A-53EF-4F85-8FA4-AA2572456CC3Q58773898-507D05D2-01AD-4FC5-9091-C7D5106F7BDFQ58797426-FDB776DC-9A2E-4D94-9142-55FA87A6C6EA
P2860
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
@en
type
label
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
@en
prefLabel
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
@en
P2860
P50
P1433
P1476
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
@en
P2093
Karsten A Pilones
Silvia C Formenti
P2860
P304
P356
10.1016/J.VACCINE.2015.05.105
P407
P577
2015-07-03T00:00:00Z